Inspire Medical Systems, Inc.

Fundamentals7.0
Price Action6.0
News Sentiment5.0
AI Rating
6.0

Key Drivers

  • Low leverage
  • High FCF
  • Large SG&A

AI
AI Summary

6.0

Inspire has transitioned from a high‑growth multiple call to a cash‑driven commercialization and margin‑conversion story—investors should now treat the equity as a defensive value play that needs clear evidence of sustained SG&A per‑implant reduction and flawless Inspire V supply/reimbursement execution to re‑rate. The key risk is legal/governance escalation (potential settlements, injunctions, or distracted management) that could erode the cash cushion and derail margin conversion, so monitor legal developments, weekly implant cadence, and SG&A trajectory closely.

BalanceSheet
Legal
Operations‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.0

Key Financial Insights:

  • Low leverage
  • High FCF
  • Large SG&A

Strong balance sheet and cash-generation (low leverage, high cash and FCF) offset by outsized operating expenses that compress margins and create volatility.

BalanceSheet
CostPressure

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Strong downside momentum
  • Support at low
  • Resistance cluster

INSP is in a clear short-term downtrend—down ~21–22% from $68.05 to $53.72 over the last month, trading well below the ~$60 21-day SMA with immediate support at $53.72 and resistance in the $59–65 band, where a break below support would deepen the bearish case while a reclaim above ~$60 would be the first sign of reversal.

bearish
watch
Support Level: $53.72
Resistance Level: $59–$65

Rapid ~21–22% decline from $68.05 to $53.72 over the last month indicating elevated short-term volatility

Sentiment & News

5.0

Key News Insights:

  • Strong Q4/results
  • Analyst volatility
  • Governance probe

Inspire Medical saw mixed March 2026 signals—solid operational updates and investor outreach offset by analyst volatility, a shareholder stake sell-down and a governance investigation.

Operational
Governance

The mix of positive operational progress and investor engagement is tempered by regulatory and ownership concerns, likely keeping INSP shares volatile until clarity on the investigation and reimbursement/competitive risks emerges